EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**GIUSEPPE GORINI**

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☑	–		
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A.** Employment	Yes ☐ No ☑	–		

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes ☐ No ☑	–		
C. Non-remunerated post	Yes ☐ No ☑	–		
D. Legal representation[5]	Yes ☐ No ☑	–		

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☑ No ☐	12/2019 – 12/2024	PI of the CCM 2019 Central Actions study "Pilot Project for a Lung Cancer Screening Program Integrated with Smoking Cessation: Pathways, Subject Selection, and Diagnostic Protocols, for an HTA Evaluation," funded by the 2019 Italian Ministry of Health CCM program, from 2019 to 2023; allocated funds : €400,000 ; • PI of the study ITALUNG2 "Lung cancer screening integrated with pathways for risk reduction for people at high risk: a pilot study," funded by the Tuscany Region under the 2018 Health Research Call; from 2020 to 2024, allocated funds: €406,328	The ITALUNG2 pilot has been developed with a twin project, the CCM 2019, funded by the Italian Ministry of Health. They shared the same protocol. Thus, the CCM-ITALUNG2 pilot was implemented to evaluate the feasibility of an organized lung cancer screening (LCS) program in 5 Italian centres. Screening pathway included invitation, recruitment using dedicated screening recruiters, referral to Smoking Cessation Services (SCSs), use of Lung-RADS score for Low-Dose CT (LDCT) reading. From November 2022-May 2024, 1,144 were recruited using specific strategies: in-person invitation by general practitioners (GPs; 32%) or other healthcare personnel (16%), self-presentation (36%), phone invitation using GPs patient lists (14%). Using all above-mentioned invitation strategies enhanced equity of access compared to self-presentation only. During recruitment, smoking cessation (SC) brief advice was administered to all smokers who were also invited to visit a SC website (http://www.liberodalfumo.it/); 45% accepted referral to SCSs. Then, 21% actually attended SCS programs. At the end of the pilot, 177 (18%) reported to be continuously abstinent. Among them, 77 (44%) quitted through SCS programs.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
A (to be continued)				Finally, 723 (64%) screenees had Coronary Artery Calcification (CAC) at baseline LDCT; 78% of them were interviewed after one year: 60% had a conversation on CAC with their GPs; 38% of them performed ≥1 cardiac instrumental tests, and 22% modified/introduced ≥1 cardiovascular disease (CVD) drug (statins; antihypertensive, antidiabetic, antiplatelet drugs). LCS program may offer an opportunity to engage high-risk patients for CV primary prevention. Results on baseline round are published here: (1) Gorini G, Puliti D, Picozzi G, et al. CCM-ITALUNG2 pilot on lung cancer screening in Italy: recruitment, integration with smoking cessation and baseline results. Radiol Med 2025 Oct 4. doi: 10.1007/s11547-025-02109-5. Results on CAC are published here: (2) Gorini G, Picozzi G, Giovannoli J, et al. Coronary Artery Calcification reporting and CVD prevention in the CCM-ITALUNG2 lung cancer screening pilot in Italy. J Cardiovasc Med (Hagerstown) (in press). Results on the integration with smoking cessation will be published here: (3) Pistelli F, Gorini G, Picozzi G, et al. Integrating smoking cessation into lung cancer screening: results of the CCM-ITALUNG2 Pilot. Submitted to Nicotine & Tob Research (July 2026)

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☑	12/2019–12/2024	• Type of received support: public funds for CCM 2019 study; public funds for ITALUNG2 pilot • Received amounts: 400,000 euros for the CCM 2019 project; 408,000 euros for ITALUNG2 pilot	CCM-ITALUNG2 pilot
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☑	From 2024 to 2028	I am the Vice President of the Italian Society for Smoking Prevention and Cessation (SITAB)	The SITAB Scientific Society collects health experts on smoking prevention for adolescents, and health professionals of the NHS Smoking Cessation Centres (SCCs) for supporting quitting smoking among adults who want to quit.
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☑			

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).
[7] **Organisation** refers to a governmental, international or non-profit organisation.
[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☑			
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☑			
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☑			
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☐ No ☑			

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☑ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☑ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☑☐ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname:
Giuseppe Gorini

Date:
July 30, 2026

Signature: 

Place: Florence, Italy

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725